Form 4: Axsome Therapeutics Director Susan Mahony Granted Stock Options and Restricted Stock Units

Axsome Therapeutics, Inc. Director Susan Mahony was granted 3,166 stock options and 1,429 restricted stock units on June 6, 2025, as part of her compensation.

Summary

• Susan Mahony, a Director at Axsome Therapeutics, Inc. (AXSM), was granted new equity awards on June 6, 2025.
• The awards include 3,166 stock options with an exercise price of $111.91 per share, which will vest in full on June 6, 2026, and expire on June 6, 2035.
• Additionally, she received 1,429 Restricted Stock Units (RSUs), each representing a contingent right to one share of common stock, which will also vest in full on June 6, 2026.
• Following these transactions, Ms. Mahony beneficially owns 3,166 stock options and 1,429 RSUs directly.

Sentiment

Score: 7

Explanation: The grant of equity compensation to a director is a positive signal of alignment between management and shareholder interests, and is a routine part of compensation, indicating stability rather than distress.

Positives

• The grant of stock options and restricted stock units aligns the director's interests with those of shareholders, incentivizing long-term company performance.
• Equity compensation is a standard practice for attracting and retaining experienced board members like Susan Mahony.

Future Outlook

The filing itself does not contain forward-looking statements beyond the vesting and expiration dates of the granted equity awards.

Industry Context

This filing reflects routine equity compensation practices for board members within the biotechnology and pharmaceutical industry, aiming to align executive incentives with long-term shareholder value creation.

Comparison to Industry Standards

• The grant of stock options and restricted stock units to a director is a common form of compensation in the biopharmaceutical industry, comparable to practices at companies like Biogen Inc. or Gilead Sciences, Inc., which frequently use equity awards to incentivize and retain key personnel.
• The specific number of units and exercise price would typically be benchmarked against peer group compensation data, though such comparative data is not provided in this filing.

Related Party Transactions

• The equity grant to Susan Mahony, a director, constitutes a related party transaction as it involves compensation from the company to an insider.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's financial interests with shareholder value creation, potentially leading to more focused long-term strategic decisions.
• Employees: While not directly impacting general employees, such compensation practices set a precedent for executive and board remuneration within the company.

Next Steps

• The granted stock options and restricted stock units are scheduled to vest on June 6, 2026.
• The stock options will remain exercisable until their expiration date of June 6, 2035.

Key Dates

Keywords

Axsome Therapeutics, AXSM, SEC Form 4, Stock Options, Restricted Stock Units, Equity Compensation, Director Compensation, Susan Mahony, Insider Transaction